A Boxed Warning has been added to the label for Metformin Hydrochloride, effective 2026-05-08. This significant update highlights the risk of lactic acidosis, a serious adverse event that has been associated with postmarketing cases, including fatalities. The warning emphasizes the subtle onset of metformin-associated lactic acidosis, which can lead to severe outcomes such as hypothermia, hypotension, and resistant bradyarrhythmias.
Background
Metformin Hydrochloride is a widely prescribed medication. The addition of a Boxed Warning to its label underscores the critical importance of recognizing and managing potential severe adverse effects. Boxed Warnings, also known as black box warnings, are the strongest warnings the FDA requires for prescription drug labels when there is reasonable evidence of a serious hazard with the drug. They are intended to draw attention to serious or life-threatening risks associated with a medication.
What this means
The presence of a Boxed Warning for lactic acidosis on the Metformin Hydrochloride label requires heightened vigilance from healthcare providers. Clinicians should be aware of the potential for this serious complication, which can manifest subtly and progress rapidly. The warning specifically mentions postmarketing cases resulting in death, hypothermia, hypotension, and resistant bradyarrhythmias. This necessitates careful patient monitoring, particularly for those with risk factors for lactic acidosis, and prompt intervention if symptoms arise. Patient advocates and researchers should also be aware of this updated safety information to better inform patients and guide future research into metformin safety profiles.
Source
The information regarding this label revision for Metformin Hydrochloride was obtained from the U.S. Food and Drug Administration (FDA) through DailyMed, a service of the National Library of Medicine. The update, effective 2026-05-08, is documented on dailymed.nlm.nih.gov.